Publicaciones (52) Publicaciones en las que ha participado algún/a investigador/a

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

    Future Oncology, Vol. 15, Núm. 19, pp. 2211-2225

  3. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

  4. Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia

    JAMA Dermatology, Vol. 155, Núm. 6, pp. 724-728

  5. Breast cancer

    Nature Reviews Disease Primers, Vol. 5, Núm. 1

  6. Churg-Strauss syndrome and pregnancy. Case report and bibliographic review.

    Ginecologia y Obstetricia de Mexico, Vol. 87, Núm. 11, pp. 756-761

  7. Clinical Characterization of Immunotherapy-Related Pruritus among Patients Seen in 2 Oncodermatology Clinics

    JAMA Dermatology

  8. Clinical implications of extracellular HMGA1 in breast cancer

    International Journal of Molecular Sciences, Vol. 20, Núm. 23

  9. Corrigendum: Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis (Annals of Oncology (2012) 23 (1130-1137) DOI: 10.1093/annonc/mdr432)

    Annals of Oncology

  10. Corrigendum: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab (Annals of Oncology (2017) 28 (761-768) DOI: 10.1093/annonc/mdw695)

    Annals of Oncology

  11. Corrigendum: Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer (Annals of Oncology (2014) 25 (592–598) DOI: 10.1093/annonc/mdt543)

    Annals of Oncology

  12. Corrigendum: Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463–471) (DOI: 10.1093/annonc/mdr137)

    Annals of Oncology

  13. Corrigendum: Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors (Annals of Oncology (2012) 23 (897-902) (DOI: 10.1093/annonc/mdr348)

    Annals of Oncology

  14. Cryosurgical management of basal cell carcinoma: in vivo follow-up using reflectance confocal microscopy

    International Journal of Dermatology

  15. Effect of Early Metoprolol During ST-Segment Elevation Myocardial Infarction on Left Ventricular Strain: Feature-Tracking Cardiovascular Magnetic Resonance Substudy From the METOCARD-CNIC Trial

    JACC: Cardiovascular Imaging, Vol. 12, Núm. 7, pp. 1188-1198

  16. Efficacy of PI3K inhibitors in advanced breast cancer

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, Núm. 10, pp. x12-x20

  17. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials

    Oncologist, Vol. 24, Núm. 8, pp. 1041-1047

  18. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial

    JAMA Oncology, Vol. 5, Núm. 11, pp. 1556-1563

  19. Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

    Annals of Oncology, Vol. 30, Núm. 3, pp. 365-373

  20. Hair disorders in cancer survivors

    Journal of the American Academy of Dermatology, Vol. 80, Núm. 5, pp. 1199-1213